Synthesis, biological evaluation, and molecular docking of new series of antitumor and apoptosis inducers designed as VEGFR-2 inhibitors

被引：32

作者：

Abdallah, Abdallah E. ^{[1
]}

Mabrouk, Reda R. ^{[1
]}

Al Ward, Maged Mohammed Saleh ^{[1
]}

Eissa, Sally, I ^{[2
,3
]}

Elkaeed, Eslam B. ^{[3
]}

Mehany, Ahmed B. M. ^{[4
]}

Abo-Saif, Mariam A. ^{[5
]}

El-Feky, Ola A. ^{[5
]}

Alesawy, Mohamed S. ^{[1
]}

El-Zahabi, Mohamed Ayman ^{[1
]}

机构：

[1] Al Azhar Univ, Fac Pharm Boys, Pharmaceut Med Chem & Drug Design Dept, Cairo, Egypt

[2] Al Azhar Univ, Fac Pharm Girls, Dept Pharmaceut Chem, Cairo, Egypt

[3] AlMaarefa Univ, Coll Pharm, Dept Pharmaceut Sci, Riyadh, Saudi Arabia

[4] Al Azhar Univ, Fac Sci, Zool Dept, Cairo, Egypt

[5] Tanta Univ, Fac Pharm, Biochem Dept, Tanta, Egypt

来源：

JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY | 2022年 / 37卷 / 01期

关键词：

Anticancer; apoptosis; multi-kinase; pharmacophoric features; VEGFR-2; KINASE INHIBITORS; DISCOVERY; CANCER; DERIVATIVES; MECHANISMS; BINDING;

D O I：

10.1080/14756366.2021.2017911

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Based on quinazoline, quinoxaline, and nitrobenzene scaffolds and on pharmacophoric features of VEGFR-2 inhibitors, 17 novel compounds were designed and synthesised. VEGFR-2 IC50 values ranged from 60.00 to 123.85 nM for the new derivatives compared to 54.00 nM for sorafenib. Compounds 15(a) , 15(b) , and 15(d) showed IC50 from 17.39 to 47.10 mu M against human cancer cell lines; hepatocellular carcinoma (HepG2), prostate cancer (PC3), and breast cancer (MCF-7). Meanwhile, the first in terms of VEGFR-2 inhibition was compound 15(d) which came second with regard to antitumor assay with IC50 = 24.10, 40.90, and 33.40 mu M against aforementioned cell lines, respectively. Furthermore, Compound 15(d) increased apoptosis rate of HepG2 from 1.20 to 12.46% as it significantly increased levels of Caspase-3, BAX, and P53 from 49.6274, 40.62, and 42.84 to 561.427, 395.04, and 415.027 pg/mL, respectively. Moreover, 15(d) showed IC50 of 253 and 381 nM against HER2 and FGFR, respectively.

引用

页码：573 / 591

页数：19

共 50 条

[1] New Series of VEGFR-2 Inhibitors and Apoptosis Enhancers: Design, Synthesis and Biological Evaluation
Abdallah, Abdallah E.
Mabrouk, Reda R.
Elnagar, Mohamed R.
Farrag, Amel Mostafa
Kalaba, Mohamed H.
Sharaf, Mohamed H.
El-Fakharany, Esmail M.
Bakhotmah, Dina Abed
Elkaeed, Eslam B.
Al Ward, Maged Mohammed Saleh
DRUG DESIGN DEVELOPMENT AND THERAPY, 2022, 16 : 587 - 606
[2] Design, synthesis, docking, ADMET studies, and anticancer evaluation of new 3-methylquinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers
Alanazi, Mohammed M.
Eissa, Ibrahim H.
Alsaif, Nawaf A.
Obaidullah, Ahmad J.
Alanazi, Wael A.
Alasmari, Abdullah F.
Albassam, Hussam
Elkady, Hazem
Elwan, Alaa
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2021, 36 (01) : 1760 - 1782
[3] Design, synthesis and cytotoxic evaluation of new thieno[2,3-d]pyrimidine analogues as VEGFR-2/AKT dual inhibitors, apoptosis and autophagy inducers
Abd El-Mawgoud, Heba K.
AboulMagd, Asmaa M.
Nemr, Mohamed T. M.
Hemdan, Magdy M.
Hassaballah, Aya I.
Farag, Paula S.
BIOORGANIC CHEMISTRY, 2024, 150
[4] Design and synthesis of new nicotinamides as immunomodulatory VEGFR-2 inhibitors and apoptosis inducers
Yousef, Reda G.
Eissa, Ibrahim H.
Elkady, Hazem
Mehany, Ahmed B. M.
Abo-Saif, Mariam Ali
Radwan, Mohamed M.
ElSohly, Mahmoud A.
Ibrahim, Ibrahim M.
Elwan, Alaa
El-Zahabi, Mohamed Ayman
FUTURE MEDICINAL CHEMISTRY, 2024, 16 (24) : 2583 - 2598
[5] Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors
Abdullaziz, Mona A.
Abdel-Mohsen, Heba T.
El Kerdawy, Ahmed M.
Ragab, Fatma A. F.
Ali, Mamdouh M.
Abu-bakr, Sherifa M.
Girgis, Adel S.
El Diwani, Hoda I.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 136 : 315 - 329
[6] Benzoxazole derivatives as new VEGFR-2 inhibitors and apoptosis inducers: design, synthesis, in silico studies, and antiproliferative evaluation
Taghour, Mohammed S.
Mahdy, Hazem A.
Gomaa, Maher H.
Aglan, Ahmed
Eldeib, Mahmoud Gomaa
Elwan, Alaa
Dahab, Mohammed A.
Elkaeed, Eslam B.
Alsfouk, Aisha A.
Khalifa, Mohamed M.
Eissa, Ibrahim H.
Elkady, Hazem
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2022, 37 (01) : 2063 - 2077
[7] VEGFR-2 inhibitors and apoptosis inducers: synthesis and molecular design of new benzo[g]quinazolin bearing benzenesulfonamide moiety
Ghorab, Mostafa M.
Alsaid, Mansour S.
Soliman, Aiten M.
Ragab, Fatma A.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2017, 32 (01) : 893 - 907
[8] Design, synthesis, in vitro, and in silico studies of new thiadiazol derivatives as promising VEGFR-2 inhibitors and apoptosis inducers
Mahdy, Hazem A.
Elkady, Hazem
Elgammal, Walid E.
Elkaeed, Eslam B.
Alsfouk, Aisha A.
Ibrahim, Ibrahim M.
Husein, Dalal Z.
Elkady, Mohamed A.
Metwaly, Ahmed M.
Eissa, Ibrahim H.
JOURNAL OF MOLECULAR STRUCTURE, 2024, 1316
[9] Phthalazine Derivatives as VEGFR-2 Inhibitors: Docking, ADMET, Synthesis, Design, Anticancer Evaluations, and Apoptosis Inducers
Bayoumi, Hatem Hussein
Ibrahim, Mohamed-Kamal
Dahab, Mohammed A.
Khedr, Fathalla
El-Adl, Khaled
DRUG DEVELOPMENT RESEARCH, 2025, 86 (01)
[10] Design, synthesis, molecular modeling and biological evaluation of novel Benzoxazole-Benzamide conjugates via a 2-Thioacetamido linker as potential anti-proliferative agents, VEGFR-2 inhibitors and apoptotic inducers
Eissa, Ibrahim H.
El-Haggar, Radwan
Dahab, Mohammed A.
Ahmed, Marwa F.
Mahdy, Hazem A.
Alsantali, Reem, I
Elwan, Alaa
Masurier, Nicolas
Fatahala, Samar S.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2022, 37 (01) : 1587 - 1599

← 1 2 3 4 5 →